Thermo Fisher Scientific showcased its latest innovations and expanded biopharma services at CPHI Milan 2024, including the launch of Accelerator™ Drug Development. This new offering provides 360° Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) drug development solutions, designed to speed and simplify the molecule-to-medicine journey for pharmaceutical and biotech customers.
The company announced expanded sites in Cincinnati, Ohio, and Bend, Oregon, to accelerate pre-clinical oral drug development, alongside investments in its global clinical trial network. These investments include a new GMP-certified ultra-cold facility in Bleiswijk, Netherlands, enhanced label printing in Basel, Switzerland, and expanded clinical trial logistics in Buenos Aires, Argentina.
Further strengthening its capabilities, Thermo Fisher opened an Innovation Lab in Center Valley, Pennsylvania, and a new Training Center and Aseptic Academy in Monza, Italy. The PPD clinical research business is also expanding its global laboratory services with a new bioanalytical lab in Gothenburg, Sweden, all contributing to a comprehensive suite of integrated solutions for drug development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.